ADCT Stock Overview
Provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ADC Therapeutics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.89 |
| 52 Week High | US$4.23 |
| 52 Week Low | US$1.05 |
| Beta | 1.55 |
| 1 Month Change | 56.20% |
| 3 Month Change | 12.50% |
| 1 Year Change | -54.01% |
| 3 Year Change | -74.83% |
| 5 Year Change | -94.65% |
| Change since IPO | -93.63% |
Recent News & Updates
Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results
May 17
ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues
Apr 04
Expanding ZYNLONTA Trials Will Broaden DLBCL Treatment Options
Expanding ZYNLONTA into earlier lines of DLBCL through trials could significantly boost revenue by accessing a larger patient population.Recent updates
Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results
May 17ADC Therapeutics SA's (NYSE:ADCT) 31% Dip In Price Shows Sentiment Is Matching Revenues
Apr 04Expanding ZYNLONTA Trials Will Broaden DLBCL Treatment Options
Expanding ZYNLONTA into earlier lines of DLBCL through trials could significantly boost revenue by accessing a larger patient population.ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
Mar 25Does This Valuation Of ADC Therapeutics SA (NYSE:ADCT) Imply Investors Are Overpaying?
Mar 10Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Feb 12ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL
Dec 12Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26%
Nov 16ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Jul 18Limiting Concerns On ADC Therapeutics' Prospects
Jun 06ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
May 30Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
May 10ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08Shareholder Returns
| ADCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 41.0% | 1.4% | 2.9% |
| 1Y | -54.0% | -14.7% | 11.9% |
Return vs Industry: ADCT underperformed the US Biotechs industry which returned -14.7% over the past year.
Return vs Market: ADCT underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| ADCT volatility | |
|---|---|
| ADCT Average Weekly Movement | 15.8% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: ADCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADCT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 264 | Ameet Mallik | www.adctherapeutics.com |
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
ADC Therapeutics SA Fundamentals Summary
| ADCT fundamental statistics | |
|---|---|
| Market cap | US$187.45m |
| Earnings (TTM) | -US$149.84m |
| Revenue (TTM) | US$75.82m |
2.5x
P/S Ratio-1.3x
P/E RatioIs ADCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADCT income statement (TTM) | |
|---|---|
| Revenue | US$75.82m |
| Cost of Revenue | US$115.13m |
| Gross Profit | -US$39.32m |
| Other Expenses | US$110.53m |
| Earnings | -US$149.84m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | -51.86% |
| Net Profit Margin | -197.64% |
| Debt/Equity Ratio | -185.0% |
How did ADCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 10:00 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ADC Therapeutics SA is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Naureen Quibria | Capital One Securities, Inc. |